ReviewClinical therapeutics2021
The Role of Advanced Practice Providers in the Care of Nonalcoholic Fatty Liver Disease.
Review in Clinical therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- BRIDGE to liver health: implementation of a group telehealth psychoeducational program through shared medical appointments for MASLD management.BMC public health · 2024Article
- Gastroenterology and hepatology advanced practice professional outpatient clinic team.iGIE : innovation, investigation and insights · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the United States. NAFLD presents unique challenges to conventional health care delivery. Patients require accurate, efficient risk stratification to both individualize clinical management plans and optimize subspecialty resource allocation The hepatology workforce is grossly outmatched by the demand for NAFLD referrals, however. Advanced practice providers (APPs) may be best suited to meeting the challenges of NAFLD care. This article reviews the nature and scope of APP practice, the specific needs posed by NAFLD, and the evidence supporting the comparative advantages of APPs in optimizing the outcomes of patients with NAFLD. Our goal is to show how APPs are uniquely suited to addressing the needs of patients with NAFLD who are seen in hepatology practice, with an emphasis on training philosophy and behavioral intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.